NCT01571635 is a Phase 2 clinical trial of SOTATERCEPT (ACE-011) in Beta Thalassemia Major, sponsored by Celgene.

Who is sponsoring NCT01571635?

NCT01571635 is sponsored by Celgene.

What drugs are being tested in NCT01571635?

Interventions in NCT01571635: SOTATERCEPT (ACE-011).

What condition does NCT01571635 study?

NCT01571635 studies Beta Thalassemia Major, Beta Thalassemia Intermedia.

Is NCT01571635 still recruiting?

NCT01571635 is currently terminated. Last updated 18 June 2023.

Are results published for NCT01571635?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-18 · How we verify

NCT01571635

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Terminated Phase 2 Results posted Last updated 18 June 2023

What this trial tests

Phase 2 trial testing SOTATERCEPT (ACE-011) in Beta Thalassemia Major in 46 participants. Terminated before completion.

Timeline

10 October 2012

Primary endpoint
2 July 2015

24 May 2022

Quick facts

Lead sponsor	Celgene
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	10 October 2012
Primary completion	2 July 2015
Estimated completion	24 May 2022
Sites	18 locations across France, United Kingdom, Greece, Italy

Drugs / interventions tested

SOTATERCEPT (ACE-011) — full drug profile →

Conditions studied

Beta Thalassemia Major — all drugs for Beta Thalassemia Major →
Beta Thalassemia Intermedia — all drugs for Beta Thalassemia Intermedia →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Beta Thalassemia Major or Beta Thalassemia Intermedia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose Primary · From first dose up to 28 days post the first dose

Number of participants with dose-limiting toxicities (DLT) are used to determine the potential recommended dose (PRD). PRD is defined as the highest dose with up to 1 out of 6 patients experiencing a DLT. DLT is defined as any side effects of the study treatment serious enough to prevent an increase in dose or level of treatment, including at least one of the following: Hypertension ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Hgb \> 14 g/dL sustained for four weeks; any NCI CTCAE toxicity ≥ Grade 3. Grade 3 is defined as sev

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	0
Dose Level 2: 0.5 mg/kg	0
Dose Level 3: 0.75 mg/kg	0
Dose Level 4: 1 mg/kg	0

Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment Secondary · From baseline to the last dose of study treatment (up to approximately 112 months)

Transfusion burden at baseline is defined as the total number of units of RBC transfusions that participants received within 168 days (24 weeks) prior to the first dose of study therapy. Transfusion burden during treatment is defined as the total number of RBC transfusion units that each participant received during the treatment divided by the treatment duration and multiplied by 168 days. The result is a 168-day transfusion burden average. Baseline measurement includes RBC transfusion history for transfusion dependent and non-transfusion dependent participants, starting at 168 days prior to e

≥ 25% reduction

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	0
Dose Level 2: 0.5 mg/kg	2
Dose Level 3: 0.75 mg/kg	4
Dose Level 4: 1 mg/kg	3

≥ 33% reduction

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	0
Dose Level 2: 0.5 mg/kg	2
Dose Level 3: 0.75 mg/kg	3
Dose Level 4: 1 mg/kg	1

≥ 50% reduction

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	0
Dose Level 2: 0.5 mg/kg	1
Dose Level 3: 0.75 mg/kg	2
Dose Level 4: 1 mg/kg	0

Number of Participants With Hemoglobin Level Increase From Baseline in Non-Transfusion Dependent B-Thalassemia Intermedia Participants Secondary · Measurements were taken in 9 and 12-week intervals, from baseline up to approximately 112 months

The Number of participants with a change in Hemoglobin levels will be listed for non-RBC transfusion dependent participants. Baseline assessments are the average of the last two measurements prior to the start of therapy.

9-week episode with Hgb ≥ 1.0 g/dl change from baseline (non-transfusion dependent participants)

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	5
Dose Level 2: 0.5 mg/kg	4
Dose Level 3: 0.75 mg/kg	6
Dose Level 4: 1 mg/kg	2

9-week episode with Hgb ≥ 1.5 g/dl change from baseline (non-transfusion dependent participants)

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	2
Dose Level 2: 0.5 mg/kg	2
Dose Level 3: 0.75 mg/kg	6
Dose Level 4: 1 mg/kg	1

12-Week episode with Hgb ≥ 1.0 g/dl change from baseline (non-transfusion dependent participants)

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	4
Dose Level 2: 0.5 mg/kg	4
Dose Level 3: 0.75 mg/kg	6
Dose Level 4: 1 mg/kg	1

12-Week episode with Hgb ≥ 1.5 g/dl change from baseline (non-transfusion dependent participants)

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	2
Dose Level 2: 0.5 mg/kg	2
Dose Level 3: 0.75 mg/kg	6
Dose Level 4: 1 mg/kg	1

Number of Participants Experiencing Adverse Events (AEs) Secondary · From first dose up to 112 days after the last dose of study treatment (up to 115 months)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events a

Participants with at least one TEAE

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	8
Dose Level 1b: 0.3 mg/kg	9
Dose Level 2: 0.5 mg/kg	8
Dose Level 3: 0.75 mg/kg	12
Dose Level 4: 1 mg/kg	9

TEAE leading to dose interruption

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	2
Dose Level 1b: 0.3 mg/kg	5
Dose Level 2: 0.5 mg/kg	4
Dose Level 3: 0.75 mg/kg	2
Dose Level 4: 1 mg/kg	5

Participants with at least one serious TEAE

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	3
Dose Level 1b: 0.3 mg/kg	3
Dose Level 2: 0.5 mg/kg	3
Dose Level 3: 0.75 mg/kg	3
Dose Level 4: 1 mg/kg	3

Participants with at least one grade 2/3/4 TEAE

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	7
Dose Level 1b: 0.3 mg/kg	9
Dose Level 2: 0.5 mg/kg	6
Dose Level 3: 0.75 mg/kg	11
Dose Level 4: 1 mg/kg	9

Participants with at least one drug-related grade 2/3/4 TEAE

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	4
Dose Level 1b: 0.3 mg/kg	3
Dose Level 2: 0.5 mg/kg	4
Dose Level 3: 0.75 mg/kg	7
Dose Level 4: 1 mg/kg	7

Participants with at least one serious drug- related TEAE

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	2
Dose Level 1b: 0.3 mg/kg	1
Dose Level 2: 0.5 mg/kg	1
Dose Level 3: 0.75 mg/kg	0
Dose Level 4: 1 mg/kg	1

Participants with at least one TEAE leading to sotatercept withdrawal

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	3
Dose Level 1b: 0.3 mg/kg	0
Dose Level 2: 0.5 mg/kg	2
Dose Level 3: 0.75 mg/kg	3
Dose Level 4: 1 mg/kg	5

Concentrations of Sotatercept in Serum Secondary · Dose 1, Day 8; Dose 1, Day 15; Dose 2, Day 1; Dose 2, Day 8; Dose 3, Day 1; Dose 3, Day 8; Dose 4, Day 1; Dose 5, Day 1; Dose 6, Day 1

Sotatercept was administered as a subcutaneous injection every 21 days during the Treatment Period. Pharmacokinetic (PK) samples were collected at the pre-specified timepoints.

Dose 1, Day 8

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	598.3	289.2 – 1345.4
Dose Level 1b: 0.3 mg/kg	1454.05	1006.6 – 2768.3
Dose Level 2: 0.5 mg/kg	3045.45	1586.7 – 4480
Dose Level 3: 0.75 mg/kg	5837.65	3238.1 – 10590.5
Dose Level 4: 1 mg/kg	3874	2264.9 – 7003

Dose 1, Day 15

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	388.7	98.4 – 1046
Dose Level 1b: 0.3 mg/kg	1150.1	550.3 – 2158.4
Dose Level 2: 0.5 mg/kg	2329.75	952 – 3005.5
Dose Level 3: 0.75 mg/kg	4279.65	2107.8 – 6692
Dose Level 4: 1 mg/kg	2405.6	1825.3 – 4605.5

Dose 2, Day 1

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	294.75	112.9 – 547.1
Dose Level 1b: 0.3 mg/kg	770.3	317.2 – 1300.1
Dose Level 2: 0.5 mg/kg	1468.05	682 – 2550.5
Dose Level 3: 0.75 mg/kg	2955.2	1257.5 – 4450.8
Dose Level 4: 1 mg/kg	1701.5	888.6 – 4267.9

Dose 2, Day 8

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	683.1	250.1 – 1210.6
Dose Level 1b: 0.3 mg/kg	2065	1363.7 – 3626.4
Dose Level 2: 0.5 mg/kg	4136.8	1661.9 – 5573.8
Dose Level 3: 0.75 mg/kg	7753.35	5046.4 – 8805.6
Dose Level 4: 1 mg/kg	5148.1	3537.4 – 10418.7

Dose 3, Day 1

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	325.35	228.8 – 790
Dose Level 1b: 0.3 mg/kg	956.8	380.6 – 1552.6
Dose Level 2: 0.5 mg/kg	2157.3	422 – 3088.4
Dose Level 3: 0.75 mg/kg	3628.45	653.5 – 6429.1
Dose Level 4: 1 mg/kg	2602.6	822.2 – 5668.1

Dose 3, Day 8

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	758.1	444 – 1232
Dose Level 1b: 0.3 mg/kg	2319.9	1475.6 – 3667.4
Dose Level 2: 0.5 mg/kg	4507.3	2077.8 – 5762.3
Dose Level 3: 0.75 mg/kg	8373.05	5345.5 – 12177.8
Dose Level 4: 1 mg/kg	6050.8	3892.5 – 12139.6

Dose 4, Day 1

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	334.85	298 – 1014.9
Dose Level 1b: 0.3 mg/kg	1022.3	348.8 – 2096.9
Dose Level 2: 0.5 mg/kg	2441.6	784 – 2845.3
Dose Level 3: 0.75 mg/kg	4137.1	1447.1 – 6126.6
Dose Level 4: 1 mg/kg	2869.2	1478.9 – 4787.7

Dose 5, Day 1

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	385.1	287.5 – 467.5
Dose Level 1b: 0.3 mg/kg	1473.9	762.1 – 2764.4
Dose Level 2: 0.5 mg/kg	1618.8	953.4 – 3440
Dose Level 3: 0.75 mg/kg	4449.7	2340.4 – 5887.8
Dose Level 4: 1 mg/kg	3048	1125.5 – 6529.3

Number of Participants With Anti-Drug Antibody (ADA) Secondary · From first dose up to 4 months after last dose (up to approximately 116 months)

The number of participants with Anti-Sotatercept Antibody is a summary of antidrug antibody (ADA) status for ADA-evaluated participants. A participant is counted as 'positive' if there is any positive result captured during the study, a participant is counted as 'negative' if there is no positive result captured during the study. ADA data was collected Day 1 in dose schedules 1 through 6. Starting from Dose 7, ADA was measured at Day 1 every 3 Doses, then finally at the post-treatment follow-up visit at Month 2 and Month 4.

Negative

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	8
Dose Level 1b: 0.3 mg/kg	8
Dose Level 2: 0.5 mg/kg	8
Dose Level 3: 0.75 mg/kg	10
Dose Level 4: 1 mg/kg	9

Positive

Group	Value	95% CI
Dose Level 1a: 0.1 mg/kg	0
Dose Level 1b: 0.3 mg/kg	1
Dose Level 2: 0.5 mg/kg	0
Dose Level 3: 0.75 mg/kg	2
Dose Level 4: 1 mg/kg	0

Adverse events — posted to ClinicalTrials.gov

Time frame: Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 115 months). SAEs and Other AEs were assessed from first dose to 112 days following last dose (up to approximately 115 months). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dose Level 1a: 0.1 mg/kg

Serious: 3/8 (38%)

Deaths: 0/8

Dose Level 1b: 0.3 mg/kg

Serious: 3/9 (33%)

Deaths: 0/9

Dose Level 2: 0.5 mg/kg

Serious: 3/8 (38%)

Deaths: 0/8

Dose Level 3: 0.75 mg/kg

Serious: 3/12 (25%)

Deaths: 0/12

Dose Level 4: 1 mg/kg

Serious: 3/9 (33%)

Deaths: 0/9

Serious adverse events (29 terms)

Reaction	System	Dose Level 1a: 0.1 mg/kg	Dose Level 1b: 0.3 mg/kg	Dose Level 2: 0.5 mg/kg	Dose Level 3: 0.75 mg/kg	Dose Level 4: 1 mg/kg
ANAEMIA	Blood and lymphatic system disorders	—	—	—	—	—
EXTRAMEDULLARY HAEMOPOIESIS	Blood and lymphatic system disorders	—	—	—	—	—
SPLENIC INFARCTION	Blood and lymphatic system disorders	—	—	—	—	—
PERICARDIAL EFFUSION	Cardiac disorders	—	—	—	—	—
ABDOMINAL PAIN UPPER	Gastrointestinal disorders	—	—	—	—	—
SUBILEUS	Gastrointestinal disorders	—	—	—	—	—
FATIGUE	General disorders	—	—	—	—	—
LOCAL SWELLING	General disorders	—	—	—	—	—
PYREXIA	General disorders	—	—	—	—	—
ANAPHYLACTIC REACTION	Immune system disorders	—	—	—	—	—
BACTERIAL PROSTATITIS	Infections and infestations	—	—	—	—	—
CORONA VIRUS INFECTION	Infections and infestations	—	—	—	—	—
LOWER RESPIRATORY TRACT INFECTION	Infections and infestations	—	—	—	—	—
PHARYNGOTONSILLITIS	Infections and infestations	—	—	—	—	—
SUBCUTANEOUS ABSCESS	Infections and infestations	—	—	—	—	—
FALL	Injury, poisoning and procedural complications	—	—	—	—	—
FOREARM FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—
LUMBAR VERTEBRAL FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—
PELVIC FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—
PUBIS FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—
ULNA FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—
UPPER LIMB FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—
BONE PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—	—
MUSCULAR WEAKNESS	Musculoskeletal and connective tissue disorders	—	—	—	—	—
HEPATIC NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—

Other adverse events (368 terms — click to expand)

Reaction	System	Dose Level 1a: 0.1 mg/kg	Dose Level 1b: 0.3 mg/kg	Dose Level 2: 0.5 mg/kg	Dose Level 3: 0.75 mg/kg	Dose Level 4: 1 mg/kg
HEADACHE	Nervous system disorders	—	—	—	—	—
ARTHRALGIA	Musculoskeletal and connective tissue disorders	—	—	—	—	—
BACK PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—	—
PYREXIA	General disorders	—	—	—	—	—
BONE PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—	—
ABDOMINAL PAIN UPPER	Gastrointestinal disorders	—	—	—	—	—
ASTHENIA	General disorders	—	—	—	—	—
INFLUENZA	Infections and infestations	—	—	—	—	—
RHINITIS	Infections and infestations	—	—	—	—	—
NECK PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—	—
PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	—	—	—	—	—
COUGH	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
OROPHARYNGEAL PAIN	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
HYPERTENSION	Vascular disorders	—	—	—	—	—
DIARRHOEA	Gastrointestinal disorders	—	—	—	—	—
NAUSEA	Gastrointestinal disorders	—	—	—	—	—
TOOTHACHE	Gastrointestinal disorders	—	—	—	—	—
FATIGUE	General disorders	—	—	—	—	—
INFLUENZA LIKE ILLNESS	General disorders	—	—	—	—	—
BRONCHITIS	Infections and infestations	—	—	—	—	—
NASOPHARYNGITIS	Infections and infestations	—	—	—	—	—
ORAL HERPES	Infections and infestations	—	—	—	—	—
UPPER RESPIRATORY TRACT INFECTION	Infections and infestations	—	—	—	—	—
MUSCULOSKELETAL PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—	—
MYALGIA	Musculoskeletal and connective tissue disorders	—	—	—	—	—
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
NASAL CONGESTION	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
ABDOMINAL PAIN	Gastrointestinal disorders	—	—	—	—	—
CONSTIPATION	Gastrointestinal disorders	—	—	—	—	—
SERUM FERRITIN INCREASED	Investigations	—	—	—	—	—
MUSCULOSKELETAL CHEST PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—	—
DIZZINESS	Nervous system disorders	—	—	—	—	—
EXTRAMEDULLARY HAEMOPOIESIS	Blood and lymphatic system disorders	—	—	—	—	—
LYMPHADENOPATHY	Blood and lymphatic system disorders	—	—	—	—	—
PALPITATIONS	Cardiac disorders	—	—	—	—	—
TACHYCARDIA	Cardiac disorders	—	—	—	—	—
EAR PAIN	Ear and labyrinth disorders	—	—	—	—	—
TINNITUS	Ear and labyrinth disorders	—	—	—	—	—
ABDOMINAL PAIN LOWER	Gastrointestinal disorders	—	—	—	—	—
DYSPEPSIA	Gastrointestinal disorders	—	—	—	—	—

Most-reported serious reactions: ANAEMIA, EXTRAMEDULLARY HAEMOPOIESIS, SPLENIC INFARCTION, PERICARDIAL EFFUSION, ABDOMINAL PAIN UPPER, SUBILEUS, FATIGUE, LOCAL SWELLING.

Data from ClinicalTrials.gov NCT01571635 adverse events section.

Sponsor's own description

Dose finding study to determine the safety and tolerability of Sotatercept (ACE-011) in adults with Beta (β)-Thalassemia

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, et al · · 2015 · cited 424× · PMID 26309397 · DOI 10.2147/dddt.s86621
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.
Dussiot M, Maciel TT, Fricot A, Chartier C, et al · · 2014 · cited 230× · PMID 24658077 · DOI 10.1038/nm.3468
Iron metabolism: pathophysiology and pharmacology.
Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, et al · · 2021 · cited 188× · PMID 34090703 · DOI 10.1016/j.tips.2021.05.001
TGF-beta signal transduction: biology, function and therapy for diseases.
Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
Erythropoiesis: insights into pathophysiology and treatments in 2017.
Zivot A, Lipton JM, Narla A, Blanc L. · · 2018 · cited 97× · PMID 30134792 · DOI 10.1186/s10020-018-0011-z
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
Cappellini MD, Porter J, Origa R, Forni GL, et al · · 2019 · cited 62× · PMID 30337358 · DOI 10.3324/haematol.2018.198887
The role of TGFβ in hematopoiesis and myeloid disorders.
Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G. · · 2019 · cited 57× · PMID 30816330 · DOI 10.1038/s41375-019-0420-1
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD. · · 2020 · cited 54× · PMID 32557398 · DOI 10.1007/s40265-020-01341-9

Verify or expand the search:

Other recruiting trials for Beta Thalassemia Major

Currently open trials in the same condition.

NCT06466304 — Inspiratory Muscle Training in Children With Beta Thalasemia · NA · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01571635 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01571635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing